Introduction
► The incidence of Chronic Obstructive Pulmonary Disease (COPD) is rising; the World Health Organization estimates that COPD will become the third leading cause of death worldwide by 2030. 1 ► COPD treatments are poorly adhered to, which can result in tremendous direct and indirect costs, thus putting a strain on national healthcare systems. 2 ► Under-adherence to COPD prescription medications (Rxs) has been estimated to be almost half of all patients, about 48%. 3 ► Indirect methods, such as self-reported adherence, can be useful in determining COPD adherence; identifying risk factors is key to informing which patient behaviors can be targeted to improve adherence. 4
Objectives ► To examine correlates of non-adherence to drug therapy among COPD patients in 5EU.
► To identify factors that may influence patient adherence to COPD Rxs.
Methods

Data Source
► Data were taken from the 5EU (France, Germany, Italy, Spain, and UK) 2011 National Health and Wellness Survey (NHWS), a cross-sectional survey representative of the total adult populations in each 5EU market. Respondents self-reported physician diagnosis of various health conditions. ► The population of interest, COPD Rx treated patients, was defined using self-reported physician diagnosis of COPD, chronic bronchitis, or emphysema (hereafter referred to collectively as COPD) and using an Rx for any of those three conditions.
Measures
► Adherence specific to COPD Rxs was measured using the Morisky Adherence Scale 5 , which consists of four items: forgetting to take Rx, careless about taking Rx, stop taking Rx when feeling better, or stop taking Rx when feeling worse. Non-adherence was defined as answering in the positive to any of these behaviors.
► Patients self-reported demographics including sex, employment, and income as well as health habits including drinking alcohol, smoking cigarettes, and exercising.
► The co-morbidity burden was assessed using the self-reported physician diagnoses of various conditions and also the Charlson Comorbidity Index (CCI), which was calculated by weighting several comorbidities by severity and summing the result.
► COPD severity was self-assessed by respondents as mild, moderate, or severe.
► Patients indicated how much money they paid out of pocket (OOP) for Rxs for any condition in an average month. If they spent any amount on their Rxs, they were considered to incur OOP costs.
► Patients reported if they used one or more cost saving strategies (CSS) with regard to their Rxs for any condition, for example: asking for generic alternatives, ordering Rxs multiple months at a time through mail order, or requesting samples.
Analyses
► Bivariate (BV) analyses between non-adherent and adherent groups were performed with chi-square tests for categorical variables and t-tests for continuous variables.
► A binary logistic regression model was conducted to assess differences between adherence groups based on the study measures.
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Conclusions:
In 5EU, advanced age and severe COPD are associated with increased adherence, while smoking and CSS with are associated with decreased adherence. Physicians need to target their younger, less severe COPD patients to encourage greater adherence to therapy.
Note: Numbers differ from published abstract due to further analysis.
Results
► Of the n=1,263 respondents who were taking an Rx for COPD, n=539 (42.7%) were non-adherent and n=724 (57.3%) were adherent.
■ The most common reason cited for non-adherence was stopping Rx use when feeling better (25%), and the least common was stopping Rx use when feeling worse (18%) (Figure 1 ). Discussion ► In COPD Rx treated patients, smoking and using a CSS were associated with significantly greater adjusted odds of non-adherence. Conversely, increasing age and severity were associated with significantly greater adjusted odds of adherence.
Results (continued)
► Cost barriers, measured in this study as using a CSS or incurring an OOP cost, may lead to non-adherence; this finding that is consistent with other studies demonstrating that cost of medication is one of the major determinates of non-adherence to COPD Rx therapy. 6
Limitations
► Causal inferences cannot be drawn from this data due to its cross-sectional nature.
► After adjusting for covariates in the logistic regression model, age and moderate or severe COPD (relative to mild COPD) were associated with significantly greater odds of adherence, while currently smoking and use of a CSS were associated with lower odds of adherence ( Table 2 ).
► Each year of age added a 3% increase in adjusted odds of adherence (p<0.001) ( Table 2) . Moderate COPD was associated with over a 50% increase in adjusted odds of adherence compared to mild COPD (p=0.001), and severe COPD was associated with 2.5 times the adjusted odds of adherence compared to mild COPD (p<0.001).
► Smoking was associated with lower adjusted odds of adherence (p=0.006), as was using at least one CSS (p<0.001) ( Figure 2 ). ► Residing in Italy was also associated with lower adjusted odds of adherence relative to living in Germany, (p<0.001). 
. Adjusted Odds Ratios for Adherence
Conclusions ► Non-adherence to COPD Rx therapies in 5EU is more likely among current smokers and patients who use medication cost-saving strategies. Further investigation is warranted to determine whether interventions addressing these behaviors would improve adherence to COPD treatment regimens.
